ambroxol; ambroxolum
Jump to navigation
Jump to search
Indications
- experimental drug for Parkinson's disease[2]
* safe but efficancy unknown[3]
Pharmacokinetics
- crosses blood brain barrier
Mechanism of action
- mucolytic agent
- increases beta-glucocerebrosidase & alpha synuclein levels in CSF
More general terms
References
- ↑ PubChem: 2132
- ↑ 2.0 2.1 Nackerdien Z Repurposed Mucolytic Shows Promise for Neuroprotection in Parkinson's Disease.
Changes in GCase levels occurred in patients with and without GBA1 mutations. MedPage Today. anuary 29, 2020 https://www.medpagetoday.org/neurology/parkinsonsdisease/84594 - ↑ 3.0 3.1 Silveira CRA, et al. Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: https://pubmed.ncbi.nlm.nih.gov/40587145 https://jamanetwork.com/journals/jamaneurology/fullarticle/2835760